Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 9INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Castration Resistant Prostate Cancer 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NIH × bintrafusp alfa protein, human × Clear all
NCT05445882 2024-04-02

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Genitourinary

Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡